Premium
Treatment of diabetic macular edema with micropulse laser therapy
Author(s) -
El Matri K.,
Chebbi Z.,
Falfoul Y.,
Kortli M.,
Hassairi A.,
Chebil A.,
El Matri L.
Publication year - 2017
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2017.0f031
Subject(s) - medicine , diabetic macular edema , ophthalmology , visual acuity , macular edema , retinal , laser therapy , edema , diabetic retinopathy , adverse effect , surgery , laser , diabetes mellitus , optics , physics , endocrinology
Purpose The aim of the present study is to investigate the effect of Micropulse Laser Therapy ( MP ) in the treatment of diabetic macular edema ( DME ). Methods Forty eyes from 25 patients with clinically significant DME were included in the study. We used MP as first‐line therapy in cases of diffuse DME if central macular thickness ( CMT ) was < 300 μ m. However, if DME was diffuse and CMT was >400 μ m, we began anti‐ VEGF therapy to reduce CMT and improve vision as quickly as possible. We started with MP also in patients who refused intravitreal anti‐ VEGF injections, whom compromised systemically or those for whom they are not effective. Best corrected visual acuity ( BCVA ) and central macular thickness ( CMT ) were measured before, 3, 6 and 12 months after intervention, and the results were compared. Results Mean age of our patients was 60,1 years. Mean BCVA was 0.67 ± 0.37 Logmar before treatment. After three months of MP , it improved to de 0.55 ± 0.4, p = 0.024. CMT was 511.79 μm, and improved to 481.8 μm (p: 0.055) at 3 month after treatment and to 410 μm at 6 months (p: 0.004) and 257.21 μm at 12 months (p = 0.002). OCT detected early retinal reflectivity changes after treatment. All patients reported subjective improvement. No adverse events were observed during follow‐up Conclusions In this study, MP laser seems to be an effective laser to treat DME . Its attractive safety profile allows clinicians to offer earlier treatment to prevent tissue damage and the development of visual disability.